Brand and Other Names:FUDR
- Classes: Antineoplastics, Antimetabolite
Dosing & Uses
Dosage Forms & Strengths
powder for injection
GI Adenocarcinoma with Metastasis to Liver, Gallbladder, Bile Ducts
Monitor: CBC, LFTs
Gastric Cancer (Orphan)
Intraperitoneal treatment of gastric cancer
Orphan indication sponsor
- Franco Muggia, M.D.; 160 East 34th Street; New York, NY 10016
Safety & efficacy not established
Serious - Use Alternative
Significant - Monitor Closely
Frequency Not Defined
Black Box Warnings
The drug should be administered under the supervision of an experienced cancer chemotherapy physician because of the possibility of severe toxic reactions
Patient should be hospitalized for initiation of the therapy because of the risk for severe toxic reactions
Poor nutritional status
Myelosuppression (leukocyte count <5000/cu.mm or decreases rapidly, or Plts <100,000/cu.mm)
Discontinue if leukocyte count falls to <3500/cu.mm or decr rapidly, or if Plt count falls to <100,000/cu.mm)
Discontinue immediately in MI occurs
Discontinue in case of stomatitis, esophagopharyngitis, leukopenia, thrombocytopenia, intractable vomiting, GI bleeding, hemorrhage, diarrhea
Pts who have received high-dose pelvic irradiation or alkylating agents
Pregnancy & Lactation
Pregnancy Category: D
Lactation: excretion in milk unknown; contraindicated
A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA:Information not available.
Half-Life: 16 min
Metabolites: urea, fluorouracil, dihydrofluorouracil, expired CO2 metabolite
Mechanism of Action
Metabolized to 5-FU; inhibits DNA synthesis during S phase by inhibition of thymidylate synthetase
Y-site: allopurinol, cefepime
Additive: carboplatin, cisplatin, etoposide, fluorouracil, leucovorin
Y-site: amifostine, aztreonam, etoposide PO4, filgrastim, fludarabine, gemcitabine, granisetron, melphalan, ondansetron, paclitaxel, piperacillin-tazobactam, sargramostim, teniposide, thiotepa, vinorelbine
Dilute with 5 mL SWI for a final concentration of 100 mg/mL
Dilute in D5W or NS
Store reconstituted soln at 2-8°C if necessary & use within 2 wk
Use infusion pump, either external or implanted
Store intact vials at 15-30°C (59-86°F)
Reconstituted vials are stable for up to weeks under refrigeration at 2-8°C (36-46°F)
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.
The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.
|1||This drug is available at the lowest co-pay. Most commonly, these are generic drugs.|
|2||This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.|
|3||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.|
|4||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|5||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|6||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|NC||NOT COVERED – Drugs that are not covered by the plan.|
Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
Select a box to add or remove a plan.
Select a class to view formulary status for similar drugs